- Home
- TTNP vs QLGN Comparison
TTNP vs QLGN Comparison
Compare TTNP & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- QLGN
- Stock Information
- Founded
- TTNP 1991
- QLGN 1996
- Country
- TTNP United States
- QLGN United States
- Employees
- TTNP N/A
- QLGN N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- TTNP Health Care
- QLGN Health Care
- Exchange
- TTNP Nasdaq
- QLGN Nasdaq
- Market Cap
- TTNP 3.3M
- QLGN 3.4M
- IPO Year
- TTNP 1996
- QLGN N/A
- Fundamental
- Price
- TTNP $3.45
- QLGN $4.18
- Analyst Decision
- TTNP
- QLGN
- Analyst Count
- TTNP 0
- QLGN 0
- Target Price
- TTNP N/A
- QLGN N/A
- AVG Volume (30 Days)
- TTNP 28.0K
- QLGN 54.9K
- Earning Date
- TTNP 12-27-2024
- QLGN 11-14-2024
- Dividend Yield
- TTNP N/A
- QLGN N/A
- EPS Growth
- TTNP N/A
- QLGN N/A
- EPS
- TTNP N/A
- QLGN N/A
- Revenue
- TTNP $3,000.00
- QLGN N/A
- Revenue This Year
- TTNP N/A
- QLGN N/A
- Revenue Next Year
- TTNP N/A
- QLGN N/A
- P/E Ratio
- TTNP N/A
- QLGN N/A
- Revenue Growth
- TTNP N/A
- QLGN N/A
- 52 Week Low
- TTNP $3.24
- QLGN $3.34
- 52 Week High
- TTNP $14.80
- QLGN $30.50
- Technical
- Relative Strength Index (RSI)
- TTNP 40.85
- QLGN 43.01
- Support Level
- TTNP $3.25
- QLGN $3.53
- Resistance Level
- TTNP $3.85
- QLGN $4.39
- Average True Range (ATR)
- TTNP 0.36
- QLGN 0.33
- MACD
- TTNP -0.00
- QLGN 0.06
- Stochastic Oscillator
- TTNP 24.76
- QLGN 50.98
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.